Christophe Morice

Christophe Morice has extensive experience in medicinal chemistry. Christophe is currently working as the Director of Medicinal Chemistry at Calliditas Therapeutics, where they oversee drug design, contributes to new synthetic routes, and performs SAR analysis. Christophe also manages external medicinal chemistry and ADME resources and leads drug discovery projects from hit identification to clinical candidacy.

Prior to this, Morice served as the Head of Medicinal Chemistry at Anagenesis Biotechnologies, where they managed remote teams of synthetic and medicinal chemists. Christophe played a key role in designing new chemical entities and providing medicinal chemistry expertise to support drug development strategies.

Morice also held the position of Head of Medicinal Chemistry at Prestwick Chemical, PC SAS/Bionomics Ltd for a decade. Christophe'sresponsibilities included leading a team in discovering new compounds for the treatment of Parkinson's disease and cognitive impairment in Alzheimer's disease. Christophe contributed to the licensing of an optimized lead compound to the pharmaceutical industry, currently in clinical phase II study.

Additionally, Morice worked as a Project Leader in Medicinal Chemistry at Prestwick Chemical SAS, where they focused on drug design for the treatment of Huntington's disease. Christophe also served as the Head of the Custom Synthesis Department.

Earlier in their career, Morice worked as a Post Doc in R&D at Johnson & Johnson Limited, Janssen-Cilag Pharmaceuticals, and as a Medicinal Chemist PostDoc at Eli Lilly - Faculty of Pharmacy of Strasbourg.

Overall, Christophe Morice has a strong background in medicinal chemistry with a wealth of experience in various leadership and research roles in the pharmaceutical industry.

From 1994 to 1998, Christophe Morice attended Université de Rennes I, where they obtained a PhD in Chemistry.